Core Viewpoint - PNC Financial Services Group, Inc. is expected to report improved revenues and earnings for Q2 2025, driven by higher net interest income and fee income, despite rising expenses and provisions for credit losses [1][11][18]. Financial Performance Expectations - The earnings surprise history of PNC is strong, with an average surprise of 8.39% over the last four quarters [2]. - The Zacks Consensus Estimate for Q2 earnings per share is $3.56, reflecting a year-over-year increase of 7.9% [18]. - Total revenues are projected at $5.62 billion, indicating a 3.8% year-over-year increase [18]. Net Interest Income (NII) - NII is expected to rise by 1-2% in Q2 2025, supported by stable funding and deposit costs [3][4][11]. - The Zacks Consensus Estimate for NII is $3.55 billion, representing a sequential increase of 2% [5]. Loan Growth - Average loans are anticipated to increase by 1% sequentially, with projections indicating a 1.4% rise [4][5]. - Demand for commercial, industrial, real estate, and consumer loans has remained solid [4]. Non-Interest Revenues - Mortgage revenues are expected to decline by 2.7% sequentially, with estimates at $130.4 million due to stable mortgage rates [6][7]. - Asset management and brokerage income is projected to see a slight decline, with the consensus estimate at $387.8 million [8][10]. - Card and cash management revenues are expected to rise by 4.9% sequentially, with estimates at $726.4 million [12]. Expenses and Asset Quality - Non-interest expenses are projected to be stable at $3.43 billion, despite ongoing investments in technology and digitalization [13][14]. - Provisions for credit losses are expected to increase to $252.5 million, a sequential rise of 15.3% [15]. - Non-performing assets (NPAs) are estimated at $2.38 billion, indicating a 2.2% increase from the previous quarter [16]. Market Conditions - Global M&A activity has improved, with deal-making resuming towards the end of the quarter despite initial market volatility due to tariff announcements [9].

TMX Group's Team Impact Open the Market in Support of Brown Bagging for Calgary's Kids (BB4CK)July 11, 2025 10:25 AM EDT | Source: Toronto Stock ExchangeToronto, Ontario--(Newsfile Corp. - July 11, 2025) - Stephanie Gauthier, Executive Director, Brown Bagging for Calgary's Kids, along with team members from Brown Bagging for Calgary's Kids , joined Calgary TMX staff to open the market.Cannot view this video? Visit:https://www.youtube.com/watch?v=AmXw89EJ_80Brown Bagging for Calgary's Kids (BB4 ...

[Music] We're on the hunt for Russian spies with Norway's domestic intelligence agency, the PST. Regional Chief Yan Raldness is operating in a town right on the border with Russia. Both its ties to Moscow and proximity to key NATO bases have made it a focal point for covert operations.It's very rare to get this kind of access, particularly in such close proximity to Russia. For this community, everything with a link to Russia is treated with suspicion. They call this spy on they're following me.Everything w ...

巴西IBOVESPA指数短线波动不大，现跌0.6%。特朗普称他们对巴西前总统Bolsonaro非常不公平。 ...

Summary of Capricor Therapeutics (CAPR) Update Call Company Overview - **Company**: Capricor Therapeutics - **Focus**: Development of Daramyacel, a cell therapy candidate for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) Key Points Regulatory Update - Capricor received a Complete Response Letter (CRL) from the FDA regarding the Biologics License Application (BLA) for Daramyacel, indicating that the application does not meet the requirements for substantial evidence of effectiveness and requires more clinical data [4][5] - The review clock has been stopped until a complete response is submitted, and Capricor does not believe a new BLA will be required [5][41] - Capricor is preparing a written response to the CRL and has initiated engagement with the FDA for further discussions [5][10] Clinical Data and Efficacy - The BLA was supported by data from the HOPE-two trial, which demonstrated statistically significant benefits in cardiac function [7][8] - The HOPE-two open label extension study showed significant results in left ventricular ejection fraction with a p-value of 0.0079 [9] - Ongoing Phase III HOPE-three clinical trial is seen as a key opportunity to address the FDA's request for additional clinical data [10] - HOPE-three has completed a twelve-month evaluation of 104 DMD patients, with data expected in Q3 2025 [10] Manufacturing and Quality Control - Capricor is committed to resolving outstanding issues in the chemistry, manufacturing, and controls (CMC) section of the application [11] - The company believes that the issues raised by the FDA are resolvable in a timely manner [11] Industry Context - The FDA's decision is viewed as concerning, especially given the high unmet medical need in DMD and the innovative nature of the therapy [6][12] - Capricor emphasizes the importance of using long-term extension data and real-world evidence in evaluating therapies for rare diseases like DMD [12] Support from Medical Community - A group of leading DMD physician scientists submitted a letter to the FDA expressing support for the Daramyacel clinical program [13] - The letter highlighted their extensive experience in treating DMD and their belief in the efficacy and safety of Daramyacel [13] Future Outlook - Capricor remains committed to working collaboratively with the FDA and is optimistic about the potential for Daramyacel to receive approval [14][15] - The company aims to provide updates as they achieve clarity with the FDA regarding the path forward [69] Financial and Strategic Considerations - Capricor maintains its priority review status and is focused on addressing the FDA's concerns without needing a new BLA [48] - The partnership with NS Pharma remains strong, with continued commitment to commercialization in the U.S. despite the CRL setback [58] Additional Insights - The FDA's cancellation of the Public Advisory Committee meeting without explanation raised concerns about the review process [6] - Capricor's approach to statistical analysis in clinical trials has been a point of contention with the FDA, particularly regarding the use of parametric versus nonparametric models [30][36] This summary encapsulates the critical updates and insights from the Capricor Therapeutics conference call, highlighting the company's current challenges and future strategies in the context of regulatory approval for Daramyacel.

Core Points - Blue Lagoon Resources Inc. has officially opened its Dome Mountain Gold Mine Project, which recently received its mining permit, making it one of only nine mining permits granted in British Columbia in the past decade [1][11] - The project is notable for being a high-grade, road-accessible gold project that has reached production-ready status in recent years [1] - The opening ceremony was attended by over 100 guests, including dignitaries and representatives from various governmental agencies, highlighting the project's significance for the region [2][3] Company Overview - Blue Lagoon Resources is a Canadian publicly listed mining company focused on developing its 100% owned Dome Mountain Gold project, with a goal of becoming a cash-flowing mining company [11] - The company achieved a key milestone by obtaining a full mining permit in February 2025, which is one of only nine such permits issued in British Columbia since 2015 [11] - The company is now preparing for the start of gold production, targeting Q3 2025 [11] Project Details - The Dome Mountain Gold Mine Project features a state-of-the-art water treatment plant capable of treating over six times the current needs at the site, ensuring long-term environmental resilience [5] - Pre-production work is set to begin next week, with mining expected to commence immediately after the completion of the biological ramp-up phase of the Moving Bed Biofilm Reactor (MBBR) system, which is anticipated to take about four weeks [6][10] - The project has a strong technical team and strategic partnerships, including a long-term toll milling agreement with Nicola Mining [7][8] Community and Cultural Engagement - The opening ceremony included participation from the Lake Babine Nation, showcasing a commitment to cultural heritage and collaboration with local communities [4][5] - The presence of Hereditary Chiefs and Guardians from the Lake Babine Nation during the ceremony emphasized the importance of respectful collaboration in the mining process [4][5]

Good evening from New York. I'm Chris Hayes. 7 days after that tragic flooding in Texas, at least 121 people have been confirmed dead, while 166 are still missing.Almost a week out from the initial flooding, search and rescue operations have now shifted to a recovery phase as hope of finding survivors dwindles. And with that horrible reality front of mind, we're starting to learn the ways in which the Trump administration failed in its response to that deadly flooding. According to a eye-opening new report, ...

Why Kristi Noem Is Under Fire For Delayed FEMA Response To Texas Floods https://t.co/ZTfCuqjU11 https://t.co/ZTfCuqjU11 ...

Core Insights - Altria (MO) is positioned to potentially continue its earnings-beat streak in the upcoming report, having a history of beating earnings estimates, particularly in the last two quarters with an average surprise of 3.35% [1][2] Earnings Performance - For the last reported quarter, Altria achieved earnings of $1.23 per share, surpassing the Zacks Consensus Estimate of $1.17 per share, resulting in a surprise of 5.13% [2] - In the previous quarter, Altria was expected to post earnings of $1.27 per share but delivered $1.29 per share, yielding a surprise of 1.57% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Altria, with a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of an earnings beat [5] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced a positive surprise nearly 70% of the time [6] Current Earnings ESP and Outlook - Altria currently has an Earnings ESP of +0.42%, suggesting analysts are optimistic about its near-term earnings potential [8] - Combined with a Zacks Rank of 2 (Buy), this indicates a strong possibility of another earnings beat in the upcoming report, expected on July 30, 2025 [8]

Core Viewpoint - NextEra Energy (NEE) is well-positioned to continue its earnings-beat streak in the upcoming report, having surpassed earnings estimates consistently in recent quarters [1][5]. Earnings Performance - In the last reported quarter, NextEra achieved earnings of $0.99 per share, exceeding the Zacks Consensus Estimate of $0.97 per share, resulting in a surprise of 2.06% [2]. - In the previous quarter, the company was expected to report earnings of $0.51 per share but delivered $0.53 per share, leading to a surprise of 3.92% [2]. Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for NextEra, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of an earnings beat [5][8]. - The current Earnings ESP for NextEra stands at +1.98%, suggesting increased analyst optimism regarding its near-term earnings potential [8]. Zacks Rank and Success Rate - NextEra holds a Zacks Rank of 3 (Hold), which, when combined with a positive Earnings ESP, indicates a high probability of beating consensus estimates, with historical data showing nearly 70% success in such cases [6][8].